Emil Kakkis, Ultragenyx CEO

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

SAN FRAN­CIS­CO — Ul­tragenyx, the com­mer­cial-stage Cal­i­for­nia biotech work­ing on ul­tra-rare dis­eases, is fin­ish­ing up a $50 mil­lion Se­ries A fundraise for its Alzheimer’s gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.